MediWound Ltd. (MDWD)

Market Cap	149.68M
Revenue (ttm)	18.69M
Net Income (ttm)	-6.72M
Shares Out	9.49M
EPS (ttm)	-0.75
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	106,829
Open	16.79
Previous Close	16.99
Day's Range	15.47 - 16.91
52-Week Range	7.10 - 18.75
Beta	0.93
Analysts	Strong Buy
Price Target	32.00 (+102.92%)
Earnings Date	May 28, 2024

About MDWD

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other ha...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 20, 2014
• Employees: 100
• Stock Exchange: NASDAQ
• Ticker Symbol: MDWD

Financial Performance

In 2023, MediWound's revenue was $18.69 million, a decrease of -29.48% compared to the previous year's $26.50 million. Losses were -$6.72 million, -65.73% less than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for MDWD stock is "Strong Buy." The 12-month stock price forecast is $32.0, which is an increase of 102.92% from the latest price.

Price Target

$32.0

(102.92% upside)

Analyst Consensus: Strong Buy